<DOC>
	<DOCNO>NCT00772109</DOCNO>
	<brief_summary>This study design test lot consistency three different manufacture lot generate safety immunogenicity data investigational vaccine administer via ID route . Primary Objective : - To demonstrate lot consistency Fluzone ID manufacturing process . - To provide information concern immune response Fluzone ID . Secondary Objectives : Safety - To describe safety profile subject receive Fluzone ID .</brief_summary>
	<brief_title>Study Fluzone Vaccine Administered Intradermal Route Comparison With Standard Fluzone® Adults</brief_title>
	<detailed_description>Three lot investigational Fluzone vaccine 2008/2009 Northern Hemisphere formulation administer intradermally ( ID ) use Becton Dickinson Micro Injection System .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 64 year day vaccination . Informed consent form sign date . Able attend schedule visit comply trial procedure . For woman child bear potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior vaccination , least 4 week vaccination . Exclusion Criteria : Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . For woman childbearing potential : know pregnancy positive serum/urine pregnancy test . Breastfeeding woman . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure four week precede trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Chronic illness , stage could interfere trial conduct completion , opinion investigator . Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure . Receipt blood bloodderived product past 3 month might interfere assessment immune response . Receipt vaccination 4 week precede trial vaccination . Planned receipt vaccine 4 week follow trial vaccination . Previous vaccination influenza past 6 month trial vaccine another vaccine . Thrombocytopenia bleed disorder 3 week precede inclusion . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Neoplastic disease hematologic malignancy , ( except localize skin prostate cancer stable time vaccination absence therapy , subject history neoplastic disease disease free &gt; =5 year ) . Personal family history GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Fluzone®</keyword>
	<keyword>Adults</keyword>
</DOC>